hfsa 2023 cme symposium - transthyretin amyloid cardiomyopathy attr-cm
Published 11 months ago • 36 plays • Length 1:07:51Download video MP4
Download video MP3
Similar videos
-
2:42
acoramidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (attr-cm)
-
2:43
3d video understanding attr amyloidosis
-
18:48
transthyretin amyloid cardiomyopathy (attr-cm) visiting vignette
-
0:31
recognize the signs of attr-cm
-
0:50
the impact of acoramidis on clinical outcomes in attr-cm
-
8:21
the cardionerds and dr. kevin alexander discuss attr-cm and transthyretin instability
-
1:25
inaugural treatment for transthyretin amyloid cardiomyopathy
-
1:05:17
hfpef phenotypes: hocm and cardiac amyloidosis in 2023
-
44:58
amyloid cardiomyopathy cme
-
15:53
icer midwest cepac public meeting on transthyretin amyloid cardiomyopathy: oral comment
-
4:40
esc 23: attribute-cm trial
-
48:59
icer midwest cepac public meeting on transthyretin amyloid cardiomyopathy: voting questions
-
3:33
how biomarkers such as nt-proβnp-1 help define progression in attr-cm
-
2:05
patisiran for transthyretin cardiac amyloidosis | nejm
-
2:55
detect attr-cm
-
8:26
expert insights into amyloidosis: closing diagnosis gap of cardiac amyloidosis in african americans
-
50:23
2023 aha/acc/hrs atrial fibrillation guidelines: what's new? | cardiology grand rounds
-
0:40
attr cm resolution | #shorts #hearttreatment #medicalinnovation